The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study

References

• Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):1–7. doi:10.1016/s0140-6736(19)31778-7.
   PubMed Web of Science ®Google Scholar
• Lanza A, Cirillo N, Femiano F, et al. How does acantholysis occur in pemphigus vulgaris: a critical review. J Cutan Pathol. 2006;33(6):401–412. doi:10.1111/j.0303-6987.2006.00523.x.
   PubMed Web of Science ®Google Scholar
• Melchionda V, Harman KE. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management. Clin Exp Dermatol. 2019;44(7):740–746. doi:10.1111/ced.14041.
   PubMed Web of Science ®Google Scholar
• Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. Arch Dermatol. 1996;132(2):203–212. doi:10.1001/archderm.1996.03890260105016.
   PubMedGoogle Scholar
• Martin LK, Werth VP, Villaneuva EV, et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64(5):903–908. doi:10.1016/j.jaad.2010.04.039.
   PubMed Web of Science ®Google Scholar
• Lever WF, White H. Treatment of pemphigus with corticosteroids. Results obtained in 46 patients over a period of 11 years. Arch Dermatol. 1963;87(1):12–26. doi:10.1001/archderm.1963.01590130018006.
   PubMedGoogle Scholar
• Tavakolpour S, Aryanian Z, Seirafianpour F, et al. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of pemphigus: special focus on COVID-19 pandemic concerns. Immunopharmacol Immunotoxicol. 2021;43(5):507–518. doi:10.1080/08923973.2021.1953063.
   PubMed Web of Science ®Google Scholar
• Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008;128(12):2745–2747. doi:10.1038/jid.2008.330.
   PubMed Web of Science ®Google Scholar
• Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 guideline for diagnosis and treatment–guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405–414. doi:10.1111/jdv.12772.
   PubMed Web of Science ®Google Scholar
• Musette P, Bouaziz JD. B cell modulation strategies in autoimmune diseases: new concepts. Front Immunol. 2018;9:622. doi:10.3389/fimmu.2018.00622.
   PubMed Web of Science ®Google Scholar
• Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–2040. doi:10.1016/s0140-6736(17)30070-3.
   PubMed Web of Science ®Google Scholar
• Alaeen H, Toosi R, Mahmoudi H, et al. Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab. Int J Womens Dermatol. 2019;5(5):372–377. doi:10.1016/j.ijwd.2019.05.008.
   PubMedGoogle Scholar
• Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002;47(5):785–788. doi:10.1067/mjd.2002.126273.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575–585 e571. doi:10.1016/j.jaad.2018.02.021.
   PubMed Web of Science ®Google Scholar
• Thukral S, Shinde N, Ray DS. Effect of different rituximab doses on B cell count, anti-a/B antibody titer, graft function, and infectious complications in ABO-Incompatible renal transplantation: a prospective study. Transplant Proc. 2021;53(3):970–975. doi:10.1016/j.transproceed.2020.10.008.
   PubMed Web of Science ®Google Scholar
• Schoergenhofer C, Schwameis M, Firbas C, et al. Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing. Sci Rep. 2018;8(1):124. doi:10.1038/s41598-017-17934-6.
   PubMed Web of Science ®Google Scholar
• Yancey KB. Commentary regarding clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Dermatol Ther. 2015;28(3):174–175. doi:10.1111/dth.12198.
   PubMed Web of Science ®Google Scholar
• Alaibac M. Ultra-Low dosage regimen of rituximab in autoimmune blistering skin conditions. Front Immunol. 2018;9:810. doi:10.3389/fimmu.2018.00810.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YH, Kim MR, et al. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165(3):646–651. doi:10.1111/j.1365-2133.2011.10411.x.
   PubMed Web of Science ®Google Scholar
• Londhe PJ, Kalyanpad Y, Khopkar US. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus. Indian J Dermatol Venereol Leprol. 2014;80(4):300–305. doi:10.4103/0378-6323.136832.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170(6):1341–1349. doi:10.1111/bjd.12972.
   PubMed Web of Science ®Google Scholar
• Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017;83(3):317–325. doi:10.4103/ijdvl.IJDVL_1078_14.
   PubMed Web of Science ®Google Scholar
• Horváth B, Huizinga J, Pas HH, et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166(2):405–412. doi:10.1111/j.1365-2133.2011.10663.x.
   PubMed Web of Science ®Google Scholar
• Russo I, Miotto S, Saponeri A, et al. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study. Expert Opin Biol Ther. 2020;20(6):673–678. doi:10.1080/14712598.2020.1727440.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Takebayashi T, Sato Y, et al. Grading criteria for disease severity by pemphigus disease area index. J Dermatol. 2014;41(11):969–973. doi:10.1111/1346-8138.12649.
   PubMed Web of Science ®Google Scholar
• Simpson K, Low ZM, Yap T, et al. Ultralow-dose rituximab in pemphigus: a single-Centre experience. Br J Dermatol. 2022;186(3):581–583. doi:10.1111/bjd.20819.
   PubMed Web of Science ®Google Scholar
• Chang Y, Chen X, Wang M, et al. A 10-year retrospective cohort analysis of rituximab for the treatment of pemphigus in a chinese population. J Am Acad Dermatol. 2021;85(6):1643–1645. doi:10.1016/j.jaad.2020.12.062.
   PubMedGoogle Scholar
• Zhang J, Huang X, Zhang Z, et al. Clinical observation of different doses of rituximab for the treatment of severe pemphigus: a single-center prospective cohort study. J Am Acad Dermatol. 2022;88(2):500–502. doi:10.1016/j.jaad.2022.06.1187.
   PubMed Web of Science ®Google Scholar
• Cho HH, Jin SP, Chung JH. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. J Eur Acad Dermatol Venereol. 2014;28(2):186–191. doi:10.1111/jdv.12080.
   PubMed Web of Science ®Google Scholar
• Singh N, Handa S, Mahajan R, et al. Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus. Clin Exp Dermatol. 2022;47(8):1508–1516. doi:10.1111/ced.15213.
   PubMed Web of Science ®Google Scholar
• Wang HH, Liu CW, Li YC, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928–932. doi:10.2340/00015555-2116.
   PubMed Web of Science ®Google Scholar
• Mohammed R, Milne A, Kayani K, et al. How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas. J Blood Med. 2019;10:71–84. doi:10.2147/jbm.s190784.
   PubMed Web of Science ®Google Scholar
• Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15 Suppl 1(Suppl 1):S3. doi:10.1186/ar3908.
   PubMedGoogle Scholar
• Didona D, Maglie R, Eming R, et al. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418. doi:10.3389/fimmu.2019.01418.
   PubMed Web of Science ®Google Scholar
• Hebert V, Joly P. Rituximab in pemphigus. Immunotherapy. 2018;10(1):27–37. doi:10.2217/imt-2017-0104.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 1999;134(5):445–450. doi:10.1016/s0022-2143(99)90164-6.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–2195. doi:10.1182/blood.V90.6.2188.
   PubMed Web of Science ®Google Scholar